# Savara, Inc. (SVRA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SVRA
## Company Profile
- Ticker: SVRA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Respiratory
## Stock Data
- Close: 5.37 USD
- Market cap: 1075867863 USD
- Last updated: 2026-09-03
## Business Overview
Savara is a respiratory company focused on rare lung disease and inhaled therapies. Its story is built around severe pulmonary conditions with limited treatment options.
## Why The Stock Is Moving

As of Sep 3, 2026, SVRA closed down 1.65% at $5.37. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Savara sits in specialty biopharma.

## Business Model

The company depends on clinical data, inhaled-delivery execution, and the ability to build a rare-respiratory franchise.

## Landscape Position

Savara is a niche respiratory biotech whose stock is tightly linked to trial and regulatory progress.

## Future Catalysts

- Savara’s next catalyst is MOLBREEVI in autoimmune pulmonary alveolar proteinosis, with regulatory and launch-readiness steps doing most of the work. The key question is whether the program can keep moving toward a real rare-disease commercial opportunity.

## Recent News
- 2019-02-06 13:00 EST — [Savara Provides Update on IMPALA and AVAIL Pivotal Clinical Studies](https://biopharmsignal.com/news/SVRA/savara-provides-update-on-impala-and-avail-pivotal-clinical-studies-c9f20311) — Source: Savara, Inc.
- 2018-12-19 13:00 EST — [Savara Announces Interim Results for OPTIMA Clinical Study  of Molgradex for the Treatment of NTM](https://biopharmsignal.com/news/SVRA/savara-announces-interim-results-for-optima-clinical-study-of-molgradex-for-the--ae8e5931) — Source: Savara, Inc.
- 2018-11-16 13:00 EST — [Savara to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27th](https://biopharmsignal.com/news/SVRA/savara-to-present-at-the-evercore-isi-healthconx-conference-on-tuesday-november--b77faa12) — Source: Savara, Inc.
- 2018-11-07 21:02 EST — [Savara Reports Third Quarter 2018 Financial Results and Provides Business Update](https://biopharmsignal.com/news/SVRA/savara-reports-third-quarter-2018-financial-results-and-provides-business-update-d64d7373) — Source: Savara, Inc.
- 2018-10-31 12:00 EST — [Savara Completes Enrollment in Molgradex OPTIMA Clinical Study for the Treatment of NTM](https://biopharmsignal.com/news/SVRA/savara-completes-enrollment-in-molgradex-optima-clinical-study-for-the-treatment-f4ebee85) — Source: Savara, Inc.